Neurogene

#Rare Disease #Neuroscience #Gene Therapy

Clinical-stage genetic medicines company developing treatments for rare neurological diseases, led by NGN-401 gene therapy for Rett syndrome and a proprietary gene regulation platform.

Company Info

Sector:Biotechnology — Gene Therapy

Headquarters:New York, NY, USA

Founded:2018

Website:www.neurogene.com/

Clinical Development Pipeline

NGN-401

Target: MECP2

Rett syndrome

Preclinical

Phase 1

Phase 2

Phase 3

Approved

Recent News

No recent news updates available for this company.

Leadership Team

Rachel McMinn, Ph.D.

Founder, President and Chief Executive Officer

Julie Jordan, M.D.

Chief Medical Officer

Careers & Job Openings

See all open roles

All

New York, NY

Apply Now →